Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NextCell Pharma ABFRA:65G -3.32%41 Equity-to-Asset is 0.79 as of Dec. 2025, which is 7% below its 10-year median of 0.85. GuruFocus rates FRA:65G with a GF Score™ of 41/100 and a GF Value™ of €0.06 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,412 Biotechnology companies, NextCell Pharma AB ranks better than 63.95% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. NextCell Pharma AB's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €4.67 Mil. NextCell Pharma AB's Total Assets for the quarter that ended in Dec. 2025 was €5.90 Mil.
Therefore, NextCell Pharma AB's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.79.
The historical rank and industry rank for NextCell Pharma AB's Equity-to-Asset or its related term are showing as below:
FRA:65G'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.59 Med: 0.85 Max: 0.97
Current: 0.79
During the past 9 years, the highest Equity to Asset Ratio of NextCell Pharma AB was 0.97. The lowest was 0.59. And the median was 0.85.
FRA:65G's Equity-to-Asset is ranked better than 63.95% of 1412
companies
in the Biotechnology industry
Industry Median: 0.69
vs FRA:65G: 0.79
NextCell Pharma AB (FRA:65G) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
NextCell Pharma AB Equity-to-Asset Related Terms
NextCell Pharma AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for NextCell Pharma AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:65G vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, NextCell Pharma AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCell Pharma AB Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCell Pharma AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where NextCell Pharma AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
NextCell Pharma AB's Equity to Asset Ratio for the fiscal year that ended in Aug. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NextCell Pharma AB (FRA:65G) has a Equity-to-Asset of 0.79 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on NextCell Pharma AB and its competitors. This is near median its historical median of 0.85. Over the past decade, NextCell Pharma AB's Equity-to-Asset has ranged from 0.59 to 0.97. According to the industry distribution chart, NextCell Pharma AB ranks #509 out of 1412 companies in the Biotechnology industry, placing it in the top 36%.
Is NextCell Pharma AB's Equity-to-Asset too high?
NextCell Pharma AB's current Equity-to-Asset of 0.79 is near median its 10-year median of 0.85. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 0.97. The Biotechnology industry median Equity-to-Asset is 0.69. NextCell Pharma AB's value of 0.79 is 14.5% above this industry median. Based on the distribution chart, NextCell Pharma AB ranks #509 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint. Overall, NextCell Pharma AB has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NextCell Pharma AB's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, NextCell Pharma AB ranks #509 out of 1412 companies for Equity-to-Asset. This puts NextCell Pharma AB in the upper half of its industry. The industry median Equity-to-Asset is 0.69. NextCell Pharma AB's value of 0.79 is 14.5% above this benchmark. Historically, NextCell Pharma AB's own Equity-to-Asset has ranged from 0.59 to 0.97 over the past decade. While the company's 10-year median is 0.85 vs. the industry median of 0.69, NextCell Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NextCell Pharma AB's current Equity-to-Asset of 0.79 is 14.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on NextCell Pharma AB and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NextCell Pharma AB's current Equity-to-Asset is 0.79, which is near median its own 10-year median of 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCell Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, NextCell Pharma AB (FRA:65G) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.06, compared to a current price of €0.08 — trading 31.2% above its estimated fair value. The current Equity-to-Asset is 0.79, which is near median its 10-year median of 0.85 and 14.5% above the Biotechnology industry median of 0.69. NextCell Pharma AB's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For NextCell Pharma AB (FRA:65G), the current Equity-to-Asset is 0.79 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NextCell Pharma AB (FRA:65G) Overvalued in 2026?
Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued.
The current stock price of €0.08 is trading 31.2% above its estimated GF Value™ of €0.06.
GuruFocus considers NextCell Pharma AB to be Significantly Overvalued.
Key valuation signals for FRA:65G:
Equity-to-Asset: 0.79 (near median its 10-year median of 0.85)
GF Value™: €0.06 vs. price of €0.08 (31.2% above fair value)
Industry Position: 14.5% above the Biotechnology median (#509 of 1412)
No single metric tells the full story. See the FRA:65G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
41GF Score
Get the complete analysis for FRA:65G
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:65G has been successfully added to your 
